Key facts
- MiMARK’s last known valuation is $32.9M (Oct 2025).
- It has raised $8.8M.
- Notable investors include European Innovation Council, Inveready Asset Management, Clave (Pamplona), PharmStars, CDTI Innvierte — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for MiMARK
- ·The full record, as it builds
Funding rounds
No funding rounds for MiMARK are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MiMARK
Operator of a biotech platform designed to reshape gynecological diagnostics through fluid-based testing. The company's platform utilizes gynecological fluid analysis as an approach to liquid biopsy, developing immunoassay-based diagnostics for conditions such as endometrial cancer, biomarker quantification for accuracy, reducing invasiveness, and supporting clinical decision-making, enabling healthcare providers to improve early detection, optimize patient outcomes, and women's health through innovative screening methods.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2021
- Employees
- 30
- Website
- mimark.es/
- Ownership
- Privately Held (backing)
MiMARK doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MiMARK shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MiMARK in its N-PORT filings yet. We sweep new filings monthly.